Real-World Outcomes of Subcutaneous Infliximab in a Middle Eastern IBD Cohort: A Prospective Study of Switch and De Novo Treatment Strategies

Clicks: 1
ID: 319151
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #30 of 38 articles by views in Crohn s & Colitis 360

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Subcutaneous (SC) infliximab offers pharmacokinetic and convenience advantages over intravenous (IV) therapy, but real-world data from the Middle East are lacking. This study evaluated SC infliximab outcomes in a prospective Middle Eastern IBD cohort. Methods A prospective observational cohort study was conducted in the United Arab Emirates. Adult IBD patients were enrolled as switchers (transitioning from stable IV to SC infliximab 120 mg or 240 mg Q2W) or new starters (SC 120 mg Q2W following IV induction). Clinical outcomes and pharmacokinetics were assessed. Results Fifty-eight patients were included (33 switchers [10 receiving 120 mg Q2W, 23 receiving 240 mg Q2W] and 25 new starters), with median follow-up of 10.1 months (IQR 7.3 to 12.9). In the switcher cohort, 90.9% maintained clinical remission post-switch, with stable CRP, serum albumin, and faecal calprotectin, and significant increases in median trough concentrations: 9.5 to 20.0 mcg/mL in the 120 mg group (p = 0.044) and 8.0 to 42.0 mcg/mL in the 240 mg group (p = 0.001). Among new starters, 88% achieved clinical remission post-induction, with a median post-induction trough level of 16.0 mcg/mL; significant improvements in CRP, serum albumin, and faecal calprotectin were observed. Dose intensification was required in 28% of new starters. Drug persistence was high and comparable across all groups (log-rank p = 0.61), with 12-month rates of over 92% across all cohorts. Conclusions SC infliximab is effective for both switching and de novo IBD management in a Middle Eastern population, delivering high clinical remission rates, robust drug exposure, and durable treatment persistence.
Reference Key
openalex_W7166539131 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maryam AlAhmad, N M Omar, Mohammed Nabil Quraishi
Journal Crohn s & Colitis 360
Year 2026
DOI
10.1093/crocol/otag067
URL
https://doi.org/10.1093/crocol/otag067
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.